Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7941798 | 0.79 | PGR (0.46) | KMT2AMEN1LMNAKDM4EGAA | |
| SCHEMBL7947997 | 0.77 | PGR (0.32) | RAB9ANPC1KMT2AMEN1LMNA | |
| SCHEMBL7947995 | 0.76 | ALDH1A1 (0.38) | POLBMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7948162 | 0.75 | GAA (0.37) | POLBMAPTKMT2AMEN1HTT | |
| SCHEMBL7941792 | 0.74 | SMN1; SMN2 (0.43) | POLBCYP2C9SMN1; SMN2KMT2AADORA3 | |
| SCHEMBL7941785 | 0.74 | LMNA (0.39) | POLBSMN1; SMN2RAB9AKMT2AADORA3 | |
| SCHEMBL7949731 | 0.74 | HSP90AA1 (0.41) | POLBMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7951665 | 0.74 | LMNA (0.40) | MAPTCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL14199035 | 0.72 | CDK5 (0.50) | POLBMAPTKMT2AMEN1ADORA3 | |
| SCHEMBL7949177 | 0.72 | KDM4E (0.51) | MAPTSMN1; SMN2RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6268496-B1 | GAMMA-AMINOBUTYRIC ACID RECEPTOR LIGANDS | NEUROGEN CORPORATION | 2001-07-31 | — | — | US | claimed |
| EP-0555391-A1 | CERTAIN IMIDAZOQUINOXALINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-08-18 | — | — | EP | claimed |
| WO-1992007853-A1 | CERTAIN IMIDAZOQUINOXALINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-05-14 | — | — | WO | claimed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-6268496-B1 | GAMMA-AMINOBUTYRIC ACID RECEPTOR LIGANDS | NEUROGEN CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-5744602-A | PSYCHOLOGICAL DISORDERS, ANTICONVULSANTS | NEUROGEN CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0555391-A1 | CERTAIN IMIDAZOQUINOXALINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007853-A1 | CERTAIN IMIDAZOQUINOXALINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | POLB 171/4885MAPT 4203/4885CTNNB1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.